HOW TOPICAL BETA-BLOCKER DID WONDER IN THE MANAGEMENT OF RESIDUAL HEMANGIOMA AFTER PROPRANOLOL THERAPY
Background: To determine the role of topical β- blocker in the management of residual hemangioma after propranolol therapy. Method: A retrospective study of all pediatric patients presenting with hemangioma from April 2014 to March 2019 was performed. Topical timolol gel was applied over the residual hemangioma which persisted even after one year of propranolol therapy. Result: Out of 68 patients included in this study 45 (70.3%), patients had complete resolution by one year using the treatment with propranolol. In 14 patients (21.8%) had residual lesion even after 1 year of treatment, upon which we applied topical timolol 0.5% gel for further 4 to 6 months. (Mean 5.35 months). At the end of the treatment, hemangioma was almost resolved. Conclusion: Timolol is a safer alternative to propranolol for residual hemangioma as a sequential treatment. It augments the regression of residual hemangioma with minimal side effects.